MD · XBRL financial data

Pediatrix Medical Group financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MD's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
General and administrative	53*	60	57	58	64*	59	56	61	66*	60	61	63
Total operating expenses	608*	479	662	477	463*	426	409	425	445*	435	431	436
Operating income (loss)	(111)*	16	(158)	34	39*	32	60	68	49*	42	57	65
Interest expense	10*	11	10	10	10*	9	9	9	9*	8	8	8
Income tax expense (benefit)	(15)*	4	(15)	6	3*	7	16	16	12*	9	14	18
Net income (loss)	(124)*	4	(153)	19	30*	21	39	72	34*	30	40	47
Earnings per share, basic USD per share	—	0.05	(1.84)	0.23	0.37*	0.25	0.46	0.85	0.41*	0.37	0.50	0.61
Earnings per share, diluted USD per share	—	0.05	(1.84)	0.23	0.37*	0.24	0.46	0.84	0.40*	0.36	0.49	0.59
Weighted average shares, basic millions of shares	82*	83	83	84	83*	84	85	85	82*	81	79	77
Weighted average shares, diluted millions of shares	81*	83	83	85	82*	85	86	86	85*	83	81	80

Fiscal quarters (MD's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	73	8	19	104	230	99	225	340	375	206	289	312
Marketable securities	104	107	114	117	119	120	124	123	124	123	115	114
Accounts receivable	272	284	274	287	260	243	239	231	230	225	228	232
Total current assets	483	427	429	528	640	492	613	717	764	587	660	684
Property and equipment, net	76	74	48	42	39	38	39	39	39	41	39	37
Right-of-use asset	62	—	—	—	34	—	—	—	31	—	—	—
Goodwill	1,384	1,393	1,239	1,239	1,243	1,243	1,243	1,255	1,261	1,268	1,268	1,268
Total assets	2,220	2,168	1,995	2,077	2,153	1,993	2,102	2,199	2,247	2,070	2,130	2,139
Accounts payable	35	32	32	47	46	44	42	39	37	32	28	26
Total current liabilities	389	247	310	373	434	271	341	393	459	443	502	536
Lease liability, non-current	47	48	49	40	32	31	30	28	26	27	23	23
Total liabilities	1,371	1,312	1,289	1,344	1,388	1,204	1,268	1,309	1,381	1,192	1,249	1,290
Retained earnings (accumulated deficit)	149	(145)	(298)	(279)	(249)	(228)	(189)	(117)	(83)	(54)	(14)	0
Total stockholders' equity	849	856	706	732	765	789	834	891	866	879	881	850
Total liabilities and equity	2,220	2,168	1,995	2,077	2,153	1,993	2,102	2,199	2,247	2,070	2,130	2,139
Common shares outstanding (cover page) millions of shares	84	84	86	86	86	86	87	86	83	82	81	78

Fiscal quarters (MD's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(124)*	4	(153)	19	30*	21	39	72	34*	30	40	47
Stock-based compensation	3*	3	2*	4*	3*	4	4*	5*	5*	5	5*	6*
Depreciation and amortization	9*	10	9	6	7*	5	5	6	6*	6	6	6
Net cash from operating activities	69*	(125)	107*	92*	133*	(117)	137*	137*	114*	(130)	125*	117*
Net cash from investing activities	(12)*	(16)	(13)*	(4)*	(2)*	(7)	(7)*	7*	(10)*	(12)	6*	(5)*
Proceeds from issuing common stock	1*	1	1*	1*	1*	1	1*	1*	1*	1	1*	1*
Share repurchases	0*	1	0*	0*	1*	2	0*	21*	64*	21	43*	83*
Net cash from financing activities	(5)*	76	(83)*	(3)*	(5)*	(6)	(4)*	(29)*	(69)*	(28)	(48)*	(90)*
Net change in cash	52*	(65)	11*	84*	126*	(131)	126*	115*	35*	(169)	83*	23*

SIC 8060 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8060 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Pediatrix Medical Group	312	501	117*	78.1M	Q3 FY26 10-QSep 30, 2026
Select Medical Holdings	26	1,421	38	124.0M	Q1 FY26 10-QMar 31, 2026
Community Health Systems	155	2,757	154*	141.0M	Q3 FY26 10-QSep 30, 2026
Ardent Health	724	1,622	197*	141.0M	Q2 FY26 10-QJun 30, 2026
Surgery Partners	217	not reported	59*	130.9M	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.